M
Marja Leivonen
Researcher at University of Helsinki
Publications - 37
Citations - 2849
Marja Leivonen is an academic researcher from University of Helsinki. The author has contributed to research in topics: Sleeve gastrectomy & Gastrectomy. The author has an hindex of 23, co-authored 36 publications receiving 2201 citations. Previous affiliations of Marja Leivonen include Helsinki University Central Hospital & Peijas Hospital.
Papers
More filters
Journal ArticleDOI
Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial.
Paulina Salminen,Paulina Salminen,Mika Helmiö,Mika Helmiö,Jari Ovaska,Jari Ovaska,Anne Juuti,Marja Leivonen,Pipsa Peromaa-Haavisto,Saija Hurme,Minna Soinio,Pirjo Nuutila,Pirjo Nuutila,Mikael Victorzon +13 more
TL;DR: Although gastric bypass compared with sleeve gastrectomy was associated with greater percentage excess weight loss at 5 years, the difference was not statistically significant, based on the prespecified equivalence margins.
Journal ArticleDOI
Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease
Panu K. Luukkonen,Panu K. Luukkonen,You Zhou,Sanja Sädevirta,Sanja Sädevirta,Marja Leivonen,Johanna Arola,Matej Orešič,Tuulia Hyötyläinen,Hannele Yki-Järvinen,Hannele Yki-Järvinen +10 more
TL;DR: Similar increases in liver fat and NASH are associated with a metabolically harmful saturated, ceramide-enriched liver lipidome in 'Metabolic NAFLD' but not in 'PNPLA3NAFLD', which may explain why metabolic but not PNPLA3 NAFLd increases the risk of type 2 diabetes and cardiovascular disease.
Journal ArticleDOI
SLEEVEPASS: A randomized prospective multicenter study comparing laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: preliminary results
Mika Helmiö,Mikael Victorzon,Jari Ovaska,Marja Leivonen,Anne Juuti,Nabil Jaser,Pipsa Peromaa,Pekka Tolonen,Saija Hurme,Paulina Salminen +9 more
TL;DR: At 30-day analysis SG is associated with a shorter operating time and fewer early minor complications compared to RYGB, and long-term follow-up is required to determine the effect on weight loss, resolution of obesity-related comorbidities, and improvement of quality of life.
Journal ArticleDOI
The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.
Panu K. Luukkonen,Panu K. Luukkonen,You Zhou,Tuulia Hyötyläinen,Marja Leivonen,Johanna Arola,Marju Orho-Melander,Matej Orešič,Hannele Yki-Järvinen +8 more
TL;DR: The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols and increases severity of non-alcoholic fatty liver disease in humans.
Journal ArticleDOI
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
Matej Orešič,Tuulia Hyötyläinen,Anna Kotronen,Peddinti Gopalacharyulu,Heli Nygren,Johanna Arola,Sandra Castillo,Ismo Mattila,Antti Hakkarainen,Ronald Borra,Ronald Borra,Miikka-Juhani Honka,An Verrijken,Sven Francque,Patricia Iozzo,Patricia Iozzo,Marja Leivonen,Nabil Jaser,Anne Juuti,Thorkild I. A. Sørensen,Pirjo Nuutila,Luc Van Gaal,Hannele Yki-Järvinen +22 more
TL;DR: The liver-fat-biomarker signature based on molecular lipids may provide a non-invasive tool to diagnose NAFLD, in addition to highlighting lipid molecular pathways involved in the disease.